Sanofi Stock News

A second phase 3 trial of Sanofi (SNY) and Regeneron Pharmaceuticals'' (REGN) medicine Dupixent (dupilumab) met its main and key secondary goals, showing the drug significantly reduced…

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a

Each of these companies possesses solid fundamentals and trades at reasonable valuations.

South Korean pharma company, ABL Bio, has partnered with Sanofi (SNY) in an exclusive collaboration and worldwide license agreement for ABL301, a clinical-stage bispecific antibody…

DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Sanofi (SNY) CEO Paul Hudson Presents at JPMorgan 40th Annual Healthcare Conference (Transcript)

These value stocks offer set-it-and-forget-it stability along with above-average dividends.

Shares of Exscientia PLC ( EXAI , Financial) got a nice boost last week when the U.K.-based biotech announced it signed a research collaboration and license agreement with large drugmaker Sanofi SA (

Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.

Kiplinger "insights for investors" online, first published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth list compiled

These biotech stocks could be worth watching in 2022.

Futures Rise Ahead Of Jobs Data That Could "Wreak Havoc In Markets" US index futures climbed on Friday, paring this weeks losses fractionally as investors braced for jobs data that should provide clues about the pace of Fed tightening and which is expected to come in strong (whisper number at 502k, above 447k estimate, up from 210K last month; Wednesdays ADP print was 807k, well above 410k estimate, our full preview is here ) but not too strong - remember we now live in a "good news is bad news" world - or else the market will freak out that the Fed will hike even faster than is currently expected. Nasdaq futures also showed signs of recovery after a three-day selloff even as cryptocurrencies crashed again during the Asian session. As of 730am, emini S&P futures were up 4 points or 0.1%, Nasdaq futures were 0.24% higher, or 37 points and Dow futures were unchanged.Treasuries were steady, with the two-year yield heading for the biggest weekly spike since October 2019. Crude oil headed for the longest streak of weekly gains since October on tightening supplies.

French drugmaker Sanofi SA will partner with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments, the two companies said on Friday.

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).